Insulet Corporation announced it has entered into a development agreement with Eli Lilly and Company (Lilly) to develop a new version of Insulet's OmniPod tubeless insulin delivery system, specifically designed to deliver Lilly's Humalog 200 units/mL insulin. Humalog U200 is a concentrated form of insulin used by higher insulin-requiring patients with diabetes that provides the same dose of insulin in half the volume of Lilly's Humalog U100 insulin. Insulet is partnering with Lilly on a clinical development program designed to evaluate the use of the Humalog U200 insulin formulation in Insulet's leading OmniPod tubeless insulin delivery system.

With a growing population of diabetes patients worldwide requiring higher total daily doses of insulin, this new version of the OmniPod tubeless insulin delivery system will be the first insulin pump designed specifically to deliver Humalog U200 insulin. This new delivery system represents an opportunity for diabetes patients with higher insulin requirements to benefit from the improved glycemic control compared to multiple daily injections and ease of use that Insulet's OmniPod System provides.